Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Teva Pharmaceutical Industries 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Teva Pharmaceutical Industries 2Q

Pharmaceutical sales in the quarter in North America were $2.1 billion (+36%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Teva 2Q

2Q Revenue: $3.4 billion (+20%)

2Q Earnings: $521 million (-2%)

Comments: Pharmaceutical sales in the quarter in North America were $2.1 billion (+36%). Sales in Europe were down 4% to $732 million. International sales were $481 million (+20%). Sales of Copaxone were up 21% in the quarter to $682 million. Sales of Azilect were $55 million (+31%). Sales in the women’s-health business, acquired from Barr, were $80 million (+4%). The increase reflected higher sales of the Plan B contraceptive. Sales of respiratory products were up 13% to $189 million. R&D expenses in the quarter were $169 million, or 5% of sales, compared to $198 million in 2Q08.

Sign up today for Contracting & Outsourcing 2009!
stagging_cp.rodpub.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters